The Central Drugs Standard Control Organisation (CDSCO) has issued a notice warning against manufacturers or exporters dispatching the same batch of cough syrups for testing at two different NABL accredited government laboratories. This notice was issued on 28th July, 2023.
CDSCO has stated that it has observed that cough syrup samples of same batch number, manufactured by the same manufacturer (for export purpose) is being received by two different laboratories for testing purposes. The CDSCO has emphasised that this is highly objectionable and not acceptable.
The CDSCO has therefore directed that no manufacturer or exporter shall submit the same batch numbers of cough syrup manufactured by them to two or more laboratories. Any contravention of this direction shall lead to the samples of those manufacturers or exporters not being accepted for testing by any NABL accredited government laboratories.
